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Background: Summary statistics comparing the stage at diagnosis of geographically defined populations of cancer
patients are increasingly used in public reporting to monitor geographical inequalities but may be confounded by
patient case mix. We explore the impact of case-mix adjustment on a publicly reported measure of early stage at
diagnosis in England. Methods: We analyzed data used for publicly reported statistics about the stage of patients
diagnosed with 1 of 11 solid tumours in 2015 in England, including information on cancer site (bladder, breast,
colon, rectum, kidney, lung, melanoma, non-Hodgkin lymphoma, ovarian, prostate, endometrial), age, gender,
income deprivation and population-based commissioning organization. We investigated how cancer site and
other patient characteristics influence organizational comparisons and attainment of early-stage targets (60%
of all cases diagnosed in TNM stages I–II). Results: Adjusting for patient case mix reduced between-organization
variance by more than 50%, resulting in appreciable discordance in organizational ranks (Kendall’s tau= 0.53),
with 18% (37/207) of organizations being reclassified as meeting/failing the early-stage target due to case mix.
Conclusion: Summary statistics on stage of cancer diagnosis for geographical populations currently used as public
health surveillance tools to monitor organizational inequalities need to account for patient sociodemographic
characteristics and cancer site case mix.
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Introduction
Across the world, the increasing disease burden associated withcancer is motivating new approaches to public health surveil-
lance to support cancer prevention and control. Monitoring of stage
at diagnosis for cancer patients of organizations responsible for the
planning and administration of local healthcare systems (including
screening programmes and diagnostic services) may be a
promising approach. In England, substantial recent improvements
in cancer registration have enabled the publication of annual
statistics for such geographically defined populations correspond-
ing to commissioning organizations (known as Clinical
Commissioning Groups or CCGs). These summarize, for 11
cancer sites combined, the proportion of patients who are
diagnosed at early stage.1 CCGs typically have a population of
about 250 000 residents and a varied sociodemographic profile.
As cancer incidence varies by sociodemographic group, and
certain cancer sites (e.g. lung and breast cancer) have both con-
trasting sociodemographic predictors and stage distribution,2
variation in patient case mix may confound such statistics.
Previous evidence raises concerns about chance variation and
potential bias from missing data for early-stage indicators, but
the potential influence of patient case mix poses additional
concerns.3 We therefore examined the degree by which patient
characteristics and cancer site affect observed variation in cancer
stage at diagnosis between English CCG populations.
Methods
Dataset
We analyzed data on all patients aged 30–99 diagnosed in England in
2015 with cancer of the colon (ICD10 C18), rectum (C19–C20),
lung (C33–C34), melanoma (C43), female breast (C50), endometrial
(C54), ovarian (C56–C574), prostate (C61), renal (C64) and bladder
cancer (C67) and non-Hodgkin’s lymphoma (NHL, C82–C85), the
same sites used in the English ‘early stage at diagnosis’ indicator.
These data included information on site of diagnosed tumour,
gender, age (5-year age group), Index of Multiple Deprivation
2015 income deprivation quintile,4 stage at diagnosis and CCG of
residence. We classified stage at diagnosis as ‘early’ (TNM stages I–
II) and ‘late’ (TNM stage III–IV)—consistent with the definition of
the ‘early stage at diagnosis’ indicator in current use.
Stage data were highly complete (91%, see Results), and given
empirical evidence supporting the appropriateness of complete
case analysis when comparing stage at diagnosis between CCGs,3
we included only patients with valid stage in all analyses.
Statistical analysis
Initially, we assessed how case-mix adjustment (CMA) affected the
distribution of early stage at diagnosis between CCGs using
multilevel logistic models, including CCG as a random effect. We
compared the size of the CCG random effect between models with
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and without fixed effect case-mix variables. We used the user-written
programme meresc to rescale results for fair comparisons between
these models.5–7
We subsequently considered five possible specifications of an
‘early stage at diagnosis’ indicator. Starting from a specification
without adjustment for case mix (i.e. emulating the convention in
current use), we incrementally considered case-mix factors in order
of their impact on between-CCG variance when used as single
adjustors. Cancer site had the largest impact when used as a single
adjustor (decreasing the degree of variance), followed by deprivation
quintile, while gender had minimal impact; adjusting for age at
diagnosis increased the between-CCG variance. Therefore, the five
possible specifications of the indicators comprised:
(1) No CMA
(2) Adjustment for cancer site only
(3) Adjustment for cancer site and income deprivation quintile
(4) Adjustment for cancer site, income deprivation quintile and
gender
(5) Adjustment for cancer site, income deprivation quintile, gender
and age group
We calculated the case-mix-adjusted CCG percentage of tumours
diagnosed at early stage (TNM stages I–II). We fit fixed-effects
logistic models to the whole dataset and recycled the model
estimates to predict the stage distribution for each CCG that
would have been seen if the case mix in each CCG was the same
as the whole national population of those diagnosed with these
cancers in that year.8 We assessed the impact of CMA on observed
(crude) CCG percentage of early stage at diagnosis by investigating:
(1) Change in the 5th–95th percentile of the CCG range of early-
stage proportion.
(2) The Kendall’s tau correlation between crude and case-mix-
adjusted organizational ranks in respect of the percentage of
patients diagnosed at an early stage. Kendall’s tau belongs to
the broader family of statistical measures used to examine cor-
relation and is particularly apt for examining concordance of
organizational ranks in the context of CMA.9,10 It measures the
concordance of all possible pairwise comparisons.11 A value of 1
indicates perfect agreement, 1 indicates complete disagree-
ment and 0 indicates half of comparisons were concordant
and half discordant.
Table 1 Descriptive statistics on overall sample of staged diagnoses of colon, rectal, lung, breast, endometrial, ovarian, prostate, renal,
bladder cancer, melanoma and non-Hodgkin’s lymphoma in English residents in 2015, with univariate test for differences between Clinical
Commissioning Groups (CCGs)
Factor National 5th percentile of CCGs Median CCG 95th percentile of CCGs P
Total diagnoses (of staged tumours)
189 632 100% 375.4 771 2161.80
Proportion early stage (of staged tumours) <0.001
108 750 57% 51% 57% 62%
Stage at diagnosis <0.001
1 65 497 35% 26% 31% 36%
2 43 253 23% 17% 21% 24%
3 35 331 19% 14% 17% 21%
4 45 551 24% 18% 22% 27%
Cancer site (ICD10) <0.001
Colon (C18) 20 561 11% 8% 11% 13%
Rectal (C19–C20) 10 145 5% 4% 5% 7%
Lung (C33–C34) 34 419 18% 13% 18% 26%
Melanoma (C43) 11 796 6% 3% 6% 9%
Female breast (C50) 41 697 22% 17% 22% 28%
Endometrial (C54) 6781 4% 2% 4% 5%
Ovarian (C56–C574) 4176 2% 1% 2% 3%
Prostate (C61) 35 653 19% 14% 18% 25%
Renal (C64) 7578 4% 3% 4% 6%
Bladder (C67) 7271 4% 3% 4% 5%
Non-Hodgkin’s lymphoma (C82–C85) 9555 5% 4% 5% 7%
Age at diagnosis <0.001
30–39 3599 2% 1% 2% 4%
40–44 4215 2% 1% 2% 4%
45–49 8103 4% 3% 4% 6%
50–54 12 106 6% 4% 6% 9%
55–59 15 651 8% 6% 8% 11%
60–64 21 308 11% 9% 11% 13%
65–69 31 594 17% 13% 17% 20%
70–74 28 822 15% 12% 15% 18%
75–79 27 032 14% 11% 14% 17%
80–84 20 326 11% 8% 11% 13%
85–89 11 957 6% 4% 6% 8%
90–99 4919 3% 1% 3% 4%
Gender <0.001
Men 92 977 49% 44% 49% 55%
Women 96 655 51% 46% 51% 56%
Quintile of IMD2015 income domain <0.001
Least deprived 40 630 21% 1% 17% 54%
2 42 092 22% 6% 21% 36%
3 39 012 21% 9% 19% 32%
4 35 351 19% 7% 19% 36%
Most deprived 32 547 17% 1% 14% 52%
Note: P values are from Chi-squared tests.
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(3) Changes in organizational classification according to the pay-
for-performance target threshold (whether 60% or greater
percentage of cancer patients in a CCG are diagnosed at early
stage).
We summarised results graphically by producing paired
coordinate plots showing adjusted CCG proportion early stage and
adjusted rank on the early-stage indicator under each of the five
CMA specifications we considered.
All analyses were performed in Stata v13.1.12
Results
Our dataset included 208 586 patients diagnosed in 2015, distributed
across 207 geographically defined CCG populations in England
(table 1), of whom 189 632 (91%) with known stage were
included in our analysis (see Supplementary table A1 for
breakdown of stage categories by cancer site). There were substantial
between-area differences in proportions of patients diagnosed with
specific cancer sites. For example, in the 5% of CCGs with the fewest
lung cancer patients less than one in eight patients (<12%) had lung
cancer, compared with more than a quarter of patients (>26%) in
the 5% of areas where lung cancer was most common (table 1).
There was also substantial between-area variation in the age and
deprivation distribution of people diagnosed with cancer (table 1).
Adjusting for cancer site alone (i.e. without any other case-mix
adjustor) reduced the size of between-area variance by 76.9%
(table 2). Additionally adjusting for deprivation quintile and
gender made little further difference, with cumulative reductions
of 78.2 and 78.3%. Additionally adjusting for age marginally
increased the between-area variance, so that full adjustment (i.e.
for cancer site, deprivation quintile, gender and age) reduced the
between-area variance by 77.8% compared with the unadjusted
model. Although all case-mix variables were associated with stage
at diagnosis (P< 0.001), adjusting for the three-patient characteristic
variables (deprivation, age, gender) had minimal additional impact
on between-area variance beyond adjusting for cancer site alone
(Supplementary table A2).
CMA affected the absolute and relative performance of individual
CCG (figure 1). The CCG with the highest unadjusted early-stage
proportion appears to have had average performance given its case
mix, with between one in five and one in three CCGs having better
performance in each of the case-mix-adjusted results (figure 1B).
Adjustment for cancer site, and to a lesser extent deprivation,
caused noticeable reordering of CCGs (Supplementary figure A2).
There was only moderate agreement between CCG ranks on the
crude and the (cancer site-deprivation-gender-age) adjusted
indicator (Kendall’s tau = 0.53).
CMA changed classification on pay-for-performance targets (60%
or more of all patients with monitored cancers being diagnosed in
stages I–II) for a number of CCGs (figure 2). After CMA, 37 (18%)
of all CCGs were reclassified as either meeting or failing the target of
at least 60% of their patients being diagnosed at early stage (table 2),
27 (13%) moving from above to below target and 10 (5%) in the
opposite direction (figure 2).
Discussion
Patient case mix, particularly by cancer site and deprivation, has a
substantial impact on summary statistics of early stage at diagnosis
for geographically defined populations of cancer patients. Adjusting
for case mix substantially reduces between-CCG variance and
reclassifies about one in six organizations regarding their target
attainment status—with several of them moving above or below
target.
Guidelines for the production of indicators recommend CMA
when the distribution of patient-level factors varies geographically
and these factors are strongly associated with the outcome—both
conditions being met in our study context.13–15 Some public
reporting schemes, such as for the Cancer Patient Experience
Survey in England, now use synchronous reporting of both crude
and case-mix-adjusted scores.16 The crude scores show users the
actual performance; interpreting them jointly with the adjusted
scores helps judge whether an organization attains higher or lower
scores than what could be expected by their patient case mix.
Although our study relates to a specific country setting, it has
paradigmatic implications for any country with a developed cancer
registration system who would consider public health surveillance of
stage at diagnosis of cancer, particularly when such indicators
combine information from multiple cancer sites.
We used the same national, population-based data as used in
early-stage indicators. The large sample size allows for adequately
precise estimation of the impact of CMA. Additional adjustors could
be considered, including ethnicity, comorbidity and tumour
morphology, but their contribution above and beyond that of the
four adjustors we examined is likely to be small.
There is debate about whether adjustment for measures of
socioeconomic status is justifiable. Such adjustment can be viewed
as ‘accepting’ of worse outcomes in patients from more deprived
communities, yet lack of adjustment produces performance
indicators that reflect broader socioeconomic factors than
organizational performance.17–19 In the context of our study, this
debate is largely redundant, as adjustment for cancer site greatly
dominates the degree of changes that result from additional adjust-
ments (including for deprivation, see Results, table 2 and
Supplementary Appendices 1 and 2).
Table 2 Summary of observed and modelled organizational (Clinical Commissioning Group) performance with and without case-mix
adjustment (CMA), with comparisons between results with ‘no CMA’ and those ‘with CMA’
No case-mix
adjustment
Adjusted for
cancer site only
Deprivation and
cancer site
Gender, deprivation
and cancer site
Age group,
gender, deprivation
and cancer site
Observed 5th–95th percentile range of CCG proportion
of cases diagnosed at stages I–II (absolute difference)
0.51–0.62 (0.11) 0.53–0.61 (0.08) 0.54–0.61 (0.07) 0.54–0.61 (0.07) 0.54–0.61 (0.07)
Kendall’s tau-b correlation of adjusted CCG early-stage
proportions with results obtained when no case-mix
adjustment is used
NA 0.6 0.52 0.52 0.53
% of CCGs that change classification in respect of the
‘at least 60% of cases diagnosed in stages I–II’ target
compared with when no case-mix adjustment is used
NA 16.9% 17.4% 17.4% 17.9%
Estimated reduction in rescaled variance compared with
that obtained when no CMA is used (see also Methods)
NA 76.9% 78.2% 78.3% 77.8%
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The motivating principle for our inquiry is the need for better
understanding, and better description to users, of the technical and
statistical properties of indicators in current use. The early-stage
indicator examined in our study is a summary statistic considering
multiple cancer sites. Summary indicators generally give more
precise estimates but can mask variation between sub-populations.
For example, one CCG may have a lower than average proportion of
advanced stage for patients with lung and a higher than average
proportion for breast cancer, and another CCG a higher than
average proportion for lung and lower than average for breast, but
these genuine differences may average out so that the two CCGs have
the same performance on the early-stage indicator. Summary
indicators may alert users to broad failings in certain organizations,
but have the potential to mask heterogeneity and failings in specific
domains. Identifying the full nature of such potential problems and
guiding improvement actions requires further detailed enquiry.
Our results demonstrate that the case mix of diagnosed patients
explains much of the observed variance in area statistics for stage at
diagnosis. Informative reporting of such early-stage indicators for
geographically defined populations must account for patient case
mix, particularly regarding cancer site. Taken together with prior
evidence, the findings indicate that early-stage indicators need to
account for potential bias from missing data, chance variation and
patient case mix.3 Direct standardization for cancer site alone (e.g.
using the distribution of cancer sites among the nationwide cohort
of incident patients) would be an easily implementable solution to
reduce bias due to both random and systematic differences in case
mix in the early-stage indicator, and would provide for a more
appropriate public health and health system performance measure.
Figure 1 Paired-coordinate plots tracking (A) absolute Clinical Commissioning Group (CCG) performance and (B) CCG rankings across the
different specifications of case-mix adjustment (CMA) in order from no adjustment to adjusted for all considered case-mix factors. Each light
grey line represents an individual organization (CCG). The thick black dashed line highlights the performance and ranking of the CCG with
the highest observed proportion of early stage at diagnosis without adjusting for case mix: after adjustment for cancer site around 20% of
CCGs have a higher proportion early stage than that CCG; after adjustment for other case-mix variables around 30% of the compared
organizations have a higher proportion early stage than that CCG. The thick black line highlights the performance and ranking of the
organizations with the lowest proportion early stage without adjusting for case mix
Figure 2 Observed crude proportion of patients diagnosed at an
early stage by CCG against case-mix-adjusted proportion of the
same organizational indicator, adjusted for cancer site, deprivation,
gender and age group at diagnosis. Grey circles represent CCGs
(either above or below target proportion of early stage) which
remain similarly classified after CMA, whereas black squares
represent re-classified CCGs
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We recommend the introduction of synchronous reporting of both
observed (crude) and adjusted proportions of early stage at diagnosis
to support the interpretation of such indicators and enable fair
organizational comparisons.
Supplementary data
Supplementary data are available at EURPUB online.
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Key points
 Indicators used in monitoring of inequalities often fail to
account for patient case mix
 Case mix can have a large impact on the variation between
geographic areas or organizations
 Indicators of stage at diagnosis should be adjusted for cancer
site, and potentially for other (sociodemographic) case-mix
variables
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